Endpoints News 2026-02-24 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 2026-02-24 Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Endpoints News 2026-02-23 FDA unveils long-awaited guidance on new pathway for individualized therapies
Endpoints News 2026-02-23 AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago
Endpoints News 2026-02-23 A federal experiment opens up a new market for digital health — if it works